Skip to main content

Cell Line Development Market Latest Trends, Demand and Advancement 2020 to 2027

Cell Line Development Market Latest Trends, Demand and Advancement 2020 to 2027
Cell Line Development Market
The cell line development market was valued at US$ 4,160.42 million in 2019 and is projected to reach US$ 11,219.87 million by 2027; it is expected to grow at a CAGR of 13.3% from 2020 to 2027.

North America has been witnessing growing number of COVID-19 cases since the viral outbreak. According to Worldometer, as of September 2, 2020, the number of cases has reached to 6,335,244, with 191,058 deaths, in the US. The pharmaceutical companies and research institution have shifted their research activities in finding vaccine for COVID-19, thereby putting the development of other therapeutics on hold. Moreover, many research organizations are struggling with a wide range of challenges such as reduced funding, cancelled fundraising events, and shelving projects due to economic uncertainty. Thus, the abovementioned factors are hindering the growth of the cell line development market, and the impact is likely to persist for a certain time period.

The cell line is an established cell culture, wherein the cells multiply in the apt growth medium and space for growth. Different cell lines are made from different cells. Cell lines enable stepwise alterations in the structure, physiology, and genetic makeup of cells under a customized environment. The cell line development market growth is mainly attributed to increasing adoption of regenerative medicines, rising prevalence of cancer across the globe, and soaring investments in R&D by pharmaceutical and biotechnology companies. Moreover, consistent research in drug discovery activities is further expected to foster market growth during the forecast period. However, the risk of cell line contamination is restricting the market growth.

Request for sample Report Copy at: https://www.theinsightpartners.com/sample/TIPHE100001196/

The growth of the cell line development market is attributed to factors such as increasing adoption of regenerative medicines, rising prevalence of cancer in the world, and mounting investments in R&D by pharmaceutical and biotechnology companies. However, the risks associated with cell line contamination hinder the growth of this market. Merck KGaA, Thermo Fisher Scientific Inc., Selexis SA (JSR Corporation), BioFactura, Inc., Corning Incorporated, Sartorius AG, Lonza, GENERAL ELECTRIC, LakePharma, Inc., and WuXiAppTec Group are among the leading companies operating in the global cell line development market.

The global cell line development market, based on type, is segmented into primary cell line, hybridomas, continuous cell lines, and recombinant cell lines. The recombinant cell lines segment held the largest share of the market in 2019. This growth is ascribed to the increasing demand for recombinant cell lines in the production of therapeutic recombinant proteins. However, the hybridomas segment is estimated to register the highest CAGR during the forecast period. This growth is attributed to rising research and development activities for novel biologics.

Stable cell lines are widely used in a wide range application, including biologics production, drug screening, and gene functional studies. The COVID-19 pandemic led to disruptions in all phases of drug development, and it has compelled many pharmaceutical companies and clinical research organizations (CROs) to put their clinical studies on hold. The new government policies, stay-at-home orders, social distancing norms, and widespread anxiety are among the prime challenges faced by researchers conducting the ongoing studies.

Regenerative medicines are a rapidly growing interdisciplinary field with the involvement of engineering sciences to develop clinical therapies for maintenance, repair, replacement, and enhancement of biological functions. The cell line development is a crucial and invariable part of this field as it helps understand how to treat a wide range of medical conditions, from broken bones to neurodegenerative diseases. Further, the regenerative medicines use cell-based models that have the potential to help the researchers in early-intervention treatment for degenerative diseases and traumatic injuries. Thus, the rise in adoption of regenerative medicines is fostering the demand for cell line development in the coming years.

The Report Segments Global Cell Line Development Market as Follows:

By Type

  • Primary Cell Line
  • Hybridomas
  • Continuous Cell Lines
  • Recombinant Cell Line

By Product

  • Equipment
  • Media & Reagent

By Application

  • Drug Discovery
  • Bioproduction
  • Tissue Engineering

Strategic Points Covered in Table of Content of Cell Line Development Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Cell Line Development market

Chapter 2: Exclusive Summary – the basic information of the Cell Line Development Market.
Chapter 3: Changing Impact on Market Dynamics- Drivers, Trends and Challenges & Opportunities of the Cell Line Development; Post COVID Analysis
Chapter 4: Presenting the Cell Line Development Market Factor Analysis, Post COVID Impact Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country 2020-2027
Chapter 6: Evaluating the leading manufacturers of the Cell Line Development market which consists of its Competitive Landscape, Peer Group Analysis, & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions (2021-2027)

Buy this Report Research @ https://www.theinsightpartners.com/buy/TIPHE100001196/

Media Contact
Company Name: The Insight Partners
Contact Person: Sameer Joshi
Email: Send Email
Phone: +1-646-491-9876
City: Pune
State: Maharashtra
Country: India
Website: https://www.theinsightpartners.com/


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.